Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

Date: November 30, 2016
Pages: 1630
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N84ACA70EB6EN
Leaflet:

Download PDF Leaflet

Non-Hodgkin Lymphoma - Pipeline Review, H2 2016
Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 23, 129, 99, 5, 107, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 9 and 5 molecules, respectively.Non-Hodgkin Lymphoma.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Non-Hodgkin Lymphoma Overview
Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics under Development by Companies
Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma - Pipeline Products Glance
Non-Hodgkin Lymphoma - Products under Development by Companies
Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects 1528
Non-Hodgkin Lymphoma - Discontinued Products 1561
Non-Hodgkin Lymphoma - Product Development Milestones 1574
Appendix 1584

LIST OF TABLES

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2016
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Development by Companies, H2 2016 (Contd..24)
Products under Development by Companies, H2 2016 (Contd..25)
Products under Development by Companies, H2 2016 (Contd..26)
Products under Development by Companies, H2 2016 (Contd..27)
Products under Development by Companies, H2 2016 (Contd..28)
Products under Development by Companies, H2 2016 (Contd..29)
Products under Development by Companies, H2 2016 (Contd..30)
Products under Development by Companies, H2 2016 (Contd..31)
Products under Development by Companies, H2 2016 (Contd..32)
Products under Development by Companies, H2 2016 (Contd..33)
Products under Development by Companies, H2 2016 (Contd..34)
Products under Development by Companies, H2 2016 (Contd..35)
Products under Development by Companies, H2 2016 (Contd..36)
Products under Development by Companies, H2 2016 (Contd..37)
Products under Development by Companies, H2 2016 (Contd..38)
Products under Development by Companies, H2 2016 (Contd..39)
Products under Development by Companies, H2 2016 (Contd..40)
Products under Development by Companies, H2 2016 (Contd..41)
Products under Development by Companies, H2 2016 (Contd..42)
Products under Development by Companies, H2 2016 (Contd..43)
Products under Development by Companies, H2 2016 (Contd..44)
Products under Development by Companies, H2 2016 (Contd..45)
Products under Development by Companies, H2 2016 (Contd..46)
Products under Development by Companies, H2 2016 (Contd..47)
Products under Development by Companies, H2 2016 (Contd..48)
Products under Development by Companies, H2 2016 (Contd..49)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2016
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Arvinas Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2016
Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Biogen Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Biogenomics Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2016
Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H2 2016
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by bluebird bio Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Calimmune Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp z oo, H2 2016
Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H2 2016
Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2016
Non-Hodgkin Lymphoma - Pipeline by EpiZyme Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H2 2016
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Genosco, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H2 2016
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H2 2016
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by LFB SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by mAbxience SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Medivation Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Mesoblast Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2016
Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H2 2016
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by SciTech Development LLC, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by SialoTec GmbH, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Targazyme Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Ltd, H2 2016
Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H2 2016
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Non-Hodgkin Lymphoma - Dormant Projects, H2 2016 1573
Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2016 1574
Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2016 1575
Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H2 2016 1576
Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H2 2016 1577
Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H2 2016 1578
Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H2 2016 1579
Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H2 2016 1580
Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H2 2016 1581
Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H2 2016 1582
Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H2 2016 1583
Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H2 2016 1584
Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H2 2016 1585
Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H2 2016 1586
Non-Hodgkin Lymphoma - Dormant Projects (Contd..14), H2 2016 1587
Non-Hodgkin Lymphoma - Dormant Projects (Contd..15), H2 2016 1588
Non-Hodgkin Lymphoma - Dormant Projects (Contd..16), H2 2016 1589
Non-Hodgkin Lymphoma - Dormant Projects (Contd..17), H2 2016 1590
Non-Hodgkin Lymphoma - Dormant Projects (Contd..18), H2 2016 1591
Non-Hodgkin Lymphoma - Dormant Projects (Contd..19), H2 2016 1592
Non-Hodgkin Lymphoma - Dormant Projects (Contd..20), H2 2016 1593
Non-Hodgkin Lymphoma - Dormant Projects (Contd..21), H2 2016 1594
Non-Hodgkin Lymphoma - Dormant Projects (Contd..22), H2 2016 1595
Non-Hodgkin Lymphoma - Dormant Projects (Contd..23), H2 2016 1596
Non-Hodgkin Lymphoma - Dormant Projects (Contd..24), H2 2016 1597
Non-Hodgkin Lymphoma - Dormant Projects (Contd..25), H2 2016 1598
Non-Hodgkin Lymphoma - Dormant Projects (Contd..26), H2 2016 1599
Non-Hodgkin Lymphoma - Dormant Projects (Contd..27), H2 2016 1600
Non-Hodgkin Lymphoma - Dormant Projects (Contd..28), H2 2016 1601
Non-Hodgkin Lymphoma - Dormant Projects (Contd..29), H2 2016 1602
Non-Hodgkin Lymphoma - Dormant Projects (Contd..30), H2 2016 1603
Non-Hodgkin Lymphoma - Dormant Projects (Contd..31), H2 2016 1604
Non-Hodgkin Lymphoma - Dormant Projects (Contd..32), H2 2016 1605
Non-Hodgkin Lymphoma - Discontinued Products, H2 2016 1606
Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H2 2016 1607
Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H2 2016 1608
Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H2 2016 1609
Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H2 2016 1610
Non-Hodgkin Lymphoma - Discontinued Products (Contd..5), H2 2016 1611
Non-Hodgkin Lymphoma - Discontinued Products (Contd..6), H2 2016 1612
Non-Hodgkin Lymphoma - Discontinued Products (Contd..7), H2 2016 1613
Non-Hodgkin Lymphoma - Discontinued Products (Contd..8), H2 2016 1614
Non-Hodgkin Lymphoma - Discontinued Products (Contd..9), H2 2016 1615
Non-Hodgkin Lymphoma - Discontinued Products (Contd..10), H2 2016 1616
Non-Hodgkin Lymphoma - Discontinued Products (Contd..11), H2 2016 1617
Non-Hodgkin Lymphoma - Discontinued Products (Contd..12), H2 2016 161

LIST OF FIGURES

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2016
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Cancer Non-Hodgkin Lymphoma Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 701 pages
Non-Hodgkin Lymphoma Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 588 pages

Ask Your Question

Non-Hodgkin Lymphoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: